Novartis Pharmaceuticals collaborates with Qualcomm in digital innovation with the Breezhaler(TM) inhaler device to treat COPD
(Thomson Reuters ONE) -
Novartis International AG /
Novartis Pharmaceuticals collaborates with Qualcomm in digital innovation with
the Breezhaler(TM) inhaler device to treat COPD
. Processed and transmitted by NASDAQ OMX Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
* The Breezhaler(TM) inhaler is the device for Novartis' portfolio of COPD
treatments of Onbrez and Seebri, and Ultibro, the leading LABA/LAMA
treatment
* The collaboration further supports Novartis' focus to empower patients
making it easier for them to manage their own chronic disease by having near
real time access to their own data on inhalation use
* Novartis plans to launch the next generation connected Breezhaler(TM) in
2019
Basel, January 5, 2016 - Novartis announced today a collaboration with Qualcomm
Incorporated through its subsidiary, Qualcomm Life, Inc., in digital innovation
with the Breezhaler(TM) inhaler device to treat COPD. Under this collaboration,
Qualcomm Life will provide the technology solution for the connectivity of the
next generation of the Breezhaler(TM) inhaler, a device used for Novartis'
portfolio of COPD treatments of Onbrez(TM) Breezhaler Seebri(TM) Breezhaler, and
Ultibro(TM) Breezhaler, the leading LABA/LAMA treatment.
This next generation of the Breezhaler(TM) inhaler will enable patients to have
access to their own data on the use of their inhaler in near real time. The
small, disposable and low power module contained within the inhaler device can
detect and report usage, the time that the inhaler is used, as well as
additional relevant information for patients and physicians. The module then
wirelessly sends the data to the patient's smartphone and a Novartis COPD mobile
application, which sends the data to the cloud, allowing patients and
potentially their healthcare providers to monitor their COPD. The connected
device will be ready for use by patients, with no assembly required.
"Novartis supports patients being empowered to make it easier for them to manage
their chronic conditions," said David Epstein, Head Novartis Pharmaceuticals.
"By enabling near real time data capture from the patient and the connected
Breezhaler(TM) device, patients can monitor their own adherence to the
medication they take which is vital to their health outcomes."
Novartis aims to be the first company in respiratory medicine to offer a
completely integrated, connected delivery device to provide a seamless, easy to
use and simple experience for patients.
About Ultibro Breezhaler
Ultibro Breezhaler 110/50 mcg is a once-daily LABA/LAMA dual bronchodilator
approved in the European Union (EU) as a maintenance bronchodilator treatment to
relieve symptoms in adult patients with COPD2. Clinical trials have shown that
it offers statistically significant improvements in bronchodilation compared to
treatments widely used as current standards of care, including SFC 50/500 mcg
and open-label tiotropium (18 mcg). Ultibro Breezhaler is currently approved for
use in over 80 countries worldwide, including countries within the EU and Latin
America, Japan, Canada, Switzerland and Australia. In the U.S. the treatment is
approved as a indacaterol 27.5 mcg/glycopyrrolate 15.6 mcg administered twice
daily, known as Utibron(TM) Neohaler(®).
About the Novartis COPD portfolio
Novartis is committed to addressing the unmet medical needs of COPD patients and
improving their quality of life by providing innovative medicines and devices.
The Novartis COPD portfolio includes Ultibro Breezhaler
(indacaterol/glycopyrronium bromide), Seebri(®) Breezhaler(®) (glycopyrronium
bromide) and Onbrez(®) Breezhaler(®)/Arcapta(TM) Neohaler(TM) (indacaterol),
which are all indicated as maintenance treatments for COPD patients.
Glycopyrronium bromide was exclusively licensed to Novartis in April 2005 by
Vectura and its co-development partner Sosei.
Novartis continues development of respiratory products for delivery via the low
resistance Breezhaler(®) inhalation device, which makes it suitable for patients
with different severities of airflow limitation. The Breezhaler device allows
patients to hear, feel and see that they have taken the full dose correctly.
About COPD
Chronic obstructive pulmonary disease (COPD) affects an estimated 210 million
people worldwide and is the third leading cause of death. It is progressive
(usually gets worse over time), and can be a life-threatening disease. COPD
makes it difficult to breathe, with symptoms that have a destructive impact on
patients' function (i.e. activity limitation, decreased mobility) and quality of
life. It is often considered to be a disease of later years but estimates
suggest that 50% of those with COPD are now less than 65 years old, resulting in
increases in absenteeism, premature retirement and reductions in workforce
participation.
Disclaimer
The foregoing release contains forward-looking statements that can be identified
by words such as "focus," "plans," "will," "potentially," "aims," "committed,"
"continues," or similar terms, or by express or implied discussions regarding
potential marketing authorizations for the next generation of the Breezhaler
inhaler, potential new indications or labeling for Ultibro Breezhaler, Seebri
Breezhaler, Onbrez Breezhaler and the other products in the Novartis COPD
portfolio, or regarding potential future revenues from such devices and
products. You should not place undue reliance on these statements. Such forward-
looking statements are based on the current beliefs and expectations of
management regarding future events, and are subject to significant known and
unknown risks and uncertainties. Should one or more of these risks or
uncertainties materialize, or should underlying assumptions prove incorrect,
actual results may vary materially from those set forth in the forward-looking
statements. There can be no guarantee that the next generation of the Breezhaler
inhaler will be approved for use in any market, or at any particular time.
Neither can there be any guarantee that any of the products in the Novartis COPD
portfolio will be submitted or approved for any additional indications or
labeling in any market, or at any particular time. Nor can there be any
guarantee that such devices and products will be commercially successful in the
future. In particular, management's expectations regarding the next generation
of the Breezhaler inhaler and the products in the Novartis COPD portfolio could
be affected by, among other things, the uncertainties inherent in research and
development, including unexpected clinical trial results and additional analysis
of existing clinical data; unexpected regulatory actions or delays or government
regulation generally; the company's ability to obtain or maintain proprietary
intellectual property protection; general economic and industry conditions;
global trends toward health care cost containment, including ongoing pricing
pressures; unexpected safety issues; unexpected manufacturing or quality issues,
and other risks and factors referred to in Novartis AG's current Form 20-F on
file with the US Securities and Exchange Commission. Novartis is providing the
information in this press release as of this date and does not undertake any
obligation to update any forward-looking statements contained in this press
release as a result of new information, future events or otherwise.
About Novartis
Novartis provides innovative healthcare solutions that address the evolving
needs of patients and societies. Headquartered in Basel, Switzerland, Novartis
offers a diversified portfolio to best meet these needs: innovative medicines,
eye care and cost-saving generic pharmaceuticals. Novartis is the only global
company with leading positions in these areas. In 2014, the Group achieved net
sales of USD 58.0 billion, while R&D throughout the Group amounted to
approximately USD 9.9 billion (USD 9.6 billion excluding impairment and
amortization charges). Novartis Group companies employ approximately 120,000
full-time equivalent associates. Novartis products are available in more than
180 countries around the world. For more information, please visit
http://www.novartis.com.
Novartis is on Twitter. Sign up to follow (at)Novartis at
http://twitter.com/novartis.
Novartis Media Relations
Central media line : +41 61 324 2200
Eric Althoff Catherine Steele
Novartis Global Media Relations Novartis Global Pharma Communications
+41 61 324 7999 (direct) +41-61 324 0990
+41 79 593 4202 (mobile) +41 79 845 3280
eric.althoff(at)novartis.com catherine.steele(at)novartis.com
e-mail: media.relations(at)novartis.com
For Novartis multimedia content, please visit www.thenewsmarket.com/Novartis
For questions about the site or required registration, please contact:
journalisthelp(at)thenewsmarket.com.
Novartis Investor Relations
Central phone: +41 61 324 7944
Samir Shah +41 61 324 7944 North America:
Pierre-Michel Bringer +41 61 324 1065 Richard Pulik +1 212 830 2448
Thomas Hungerbuehler +41 61 324 8425 Sloan Pavsner +1 212 830 2417
Isabella Zinck +41 61 324 7188
e-mail: investor.relations(at)novartis.com e-mail:
investor.relations(at)novartis.com
Media release (PDF) :
http://hugin.info/134323/R/1976834/723603.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Novartis International AG via GlobeNewswire
[HUG#1976834]
Unternehmensinformation / Kurzprofil:
Datum: 05.01.2016 - 23:00 Uhr
Sprache: Deutsch
News-ID 442569
Anzahl Zeichen: 11312
contact information:
Town:
Basel
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 233 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Novartis Pharmaceuticals collaborates with Qualcomm in digital innovation with the Breezhaler(TM) inhaler device to treat COPD"
steht unter der journalistisch-redaktionellen Verantwortung von
Novartis International AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
